Background: Experimental and epidemiological evidence have suggested that chronic inflammation
, Peter A. Fasching 13, 16 , Mari K. Halle 11, 12 , Alexander Hein polymorphism remained significant after Bonferroni correction and showed a significant association with endometrial cancer in both Asian-and European-ancestry samples.
Conclusions:
These findings lend support to the hypothesis that genetic polymorphisms in genes involved in the inflammatory pathway may contribute to genetic susceptibility to endometrial cancer.
INTRODUCTION
Endometrial cancer is the most common gynecological malignancy in developed countries and the second most common in the world (1, 2) . While relatively uncommon among Chinese women, its incidence has been increasing at an alarming rate. Incidence of endometrial cancer among Chinese women in urban Shanghai has increased 90% over the last two decades, from 4.0/100,000 in 1987 (3) to 7.62/100,000 in 2007 (4). Obesity, early age at menarche, late age at menopause, nulliparity, and use of estrogen hormone replacement therapy are established risk factors for endometrial cancer (5) .
Although the genetics of endometrial cancer are poorly understood, its heritability of approximately 0.5 indicates that there is a strong genetic component for disease risk. A number of lines of experimental and epidemiological evidence have indicated that inflammation may play an important role in the transition from normal endometrium to malignancy. Of the many risk factors associated with endometrial cancer, several--including use of unopposed estrogen, anovulation, endometriosis, early age at menarche, and late age at menopause--may contribute to a state of prolonged exposure to inflammation (6) . Such prolonged exposure can result in derangement of cellular processes, which could lead to excessive mitosis, the accumulation of DNA damage, and thus cancer (7, 8) . Given this evidence, we hypothesized that common genetic polymorphisms in inflammatory pathway genes may also influence the risk of this disease.
To investigate this hypothesis, a two-stage study was used to determine if common variants in genes involved in the inflammatory response were associated with endometrial cancer risk using the resources of the Shanghai Endometrial Cancer Genetics Study and ten additional studies of endometrial cancer conducted among women in the US, Australia, Europe, and China.
MATERIALS AND METHODS
This study involved two stages, as shown in Table 1 . Study populations are described below and the overall study design and SNP selection procedure are depicted in Figure 1 .
Study population
Stage 1 was conducted among the participants of the Shanghai Endometrial Cancer Genetics Study (SECGS), which included 832 cases from the Shanghai Endometrial Cancer Study (SECS) and 2,049 controls from the Shanghai Breast Cancer Study (SBCS) and the Shanghai Women's Health Study (SWHS). Details of these studies have been described previously (9) . Data for stage 2 included 6,604 cases and 8,511 controls from a total of 10 studies (Table 1 ). IRB approval was obtained for all of the parent studies from all contributing institutions, and informed consent was obtained from all participants.
Candidate SNP selection
The SNP selection scheme is shown in Figure 1 . Sixty-four candidate genes involved in inflammatory pathways were identified based on literature review and bioinformatics searches. In stage 1 a total of 4,542 SNPs with minor allele frequencies of 0.05 or greater were located in RefSeq transcripts of these genes or nearby (± 20kb).Genotyping of these SNPs was carried out as part of a larger genome-wide association study previously described (9) . Only SNPs that passed quality control (QC) from the Affymetrix 6.0 array (Affymetrix, Santa Clara, CA, USA) or that could be imputed were eligible for selection. SNPs for stage 2 were selected, using data from HapMap, release 28, after evaluation of linkage disequilibrium between the associated SNPs. From this, it was determined that the majority of associations could be linked to one of 24 distinct loci. The SNP with the lowest P value from each of the 24 loci was selected for follow-up genotyping in stage 2.
Genotyping, quality control, and imputation
Stage 1 genotyping and QC procedures have been described in detail in previous publications (9, 10 After QC was completed, the Hidden Markov Model as implemented in Mach 1.0 was used to impute the genotype for variants of interest that were not directly genotyped using Asian genotyping data from HapMap for reference genotypes (11).
In stage 2, 21 of the 24 SNPs selected for replication genotyping as described above, were successfully genotyped. Some stage 2 studies (e.g. HAECS and HJECS) genotyped fewer than 21
SNPs. Only SNPs which met QC criteria similar to that applied for stage 1 were included in the stage 2 analysis. Imputed genotypes were used for some SNPs in ANECS/NECS, NSECG, and control samples derived from the WTCCC when direct genotyping data were not available (12) .
Statistical analysis
Unconditional logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for associations between genotypes and endometrial cancer risk in stage 1. Covariates adjusted for included age, income, and education. Directly genotyped or imputed information for 4,542 SNPs was evaluated for associations with endometrial cancer and 614 SNPs showed a nominal association with endometrial cancer (P<0.05).
Unconditional logistic regression was used to analyze the 21 SNPs selected for stage 2. These analyses were adjusted for age only, because a unifying set of common demographic or anthropometric covariates was not available across all studies. Using the ORs derived from individual studies, a meta-analysis was conducted derive summary statistics (13) . An overall Z-statistic and P value based on the weighted average of the individual statistics was calculated. The resulting ORs and 95CIs are based on the fixed effect model, unless heterogeneity across studies was evident (P<0.05 for homogeneity test). In the latter case, ORs, 95 CIs, and P values derived from the random effect model are presented. All P values presented are based on two-tailed tests. The directions of association in the discovery and replication samples were consistent for all five SNPs. Of these SNPs, only the polymorphisms near CXCL3 and in MMP9 were significantly associated with endometrial cancer risk in the replication stage. No heterogeneity across studies was found for these five SNPs. Table 3 presents the heterozygous, homozygous, and per allele associations with type 1 endometrial (endometroid) cancer for the five significant SNPs among all women combined, among women of Asian ancestry, and among women of European ancestry. SNP rs3918249 in MMP9 was associated with endometrial cancer risk in women of both Asian and European ancestry. Other SNPs were not significantly associated with endometrial cancer in European-ancestry women. SNP rs10503574 in MSR1 was more significant in Asian-ancestry women than in the overall sample.
RESULTS

Stage
When restricting analyses to women with type 1 endometrial cancer, the results were largely unchanged.
DISCUSSION
The link between inflammation and endometrial cancer is supported by a great deal of experimental and epidemiological evidence, indicating that conditions related to chronic inflammation, such as prolonged menstruation, obesity, unopposed menopausal estrogen use, and other factors, tend to increase the risk of endometrial cancer (14, 15) . Menstruation itself, during which the endometrium goes through proliferative, secretory, and menstrual phases, mimics an inflammatory process and is associated with the activation of inflammatory cytokines that results in the shedding of the endometrium (15) . Estrogen directly regulates the production of a number of inflammatory cytokines, growth factors, and corresponding receptors (16) . Women who have more children or take oral contraceptives have relatively lower levels of exposure to estrogen and are at comparatively reduced risk of endometrial cancer (17) . Increased mitotic activity in endometrial epithelial cells results in increased DNA replication and repair errors; these, in turn, can lead to somatic mutations that may ultimately give rise to hyperplasia and endometrial cancer (7) .
In this large two-stage study, including samples from both Asian-and European-ancestry populations, we found that genetic variants in five candidate genes, FABP1, CXCL3, IL6, MSR1, and MMP9, were associated with endometrial cancer in combined analyses. Of these, only the CXCL3 and MMP9 polymorphisms had significant associations in the stage 2 analysis. Only rs3918249, the MMP9 variant, was associated with endometrial cancer in both Asian-and European-ancestry samples.
MMP9 encodes a matrix metalloproteinase, involved in the breakdown of the extracellular matrix, a process which has been well studied for its relationship with cancer. MMP9 is secreted from endometrial stromal cells in response to induction by growth factors, such as HGF, in endometrial cancer cell lines, which, in turn, increases cancer cell invasiveness (18) . Expression of MMP9 is known to be up-regulated through pro-inflammatory cytokines, including nuclear factor kappa B, IL8, and TNF-alpha, leading to increased tumor cell proliferation (19) (20) (21) . MMP9 expression level has been correlated to the grade and stage of endometrial cancer (22) . The MMP9 protein has been shown to be frequently expressed in endometriosis, a benign disease, in which MMP9 expression level is higher in aggressive lesions than in normal endometrium (23, 24) . MMP9 transgenic mice show significantly increased susceptibility to chemically induced cancer (25) . The significant SNP we found, rs3918249, resides in a promoter region of MMP9, and is predicted to be in a transcription factor binding site. Further, it is in linkage disequilibrium with a non-synonymous coding SNP, rs17576, in MMP9, though this is predicted to be benign by PolyPhen-2 and SIFT (26, 27) . Further investigation of the role of this gene in endometrial carcinogenesis is warranted. SNP rs352038 near the CXCL3 gene was our second most significant finding overall and, like MMP9, independently significant in the replication sample. CXCL3 is an attractive candidate gene, although rs352038 is not located in the CXCL3 gene, but 14.2kb downstream. However, it is in linkage disequilibrium with SNPs in other CXC chemokine genes in the 4q21 region, including CXCL2 and CXCL5. CXCL3 is upregulated in breast cancer, is present at higher levels in metastases, and is associated with shorter relapse-free survival in patients treated with tamoxifen (28) . Consistent with the hormonal etiology of endometrial cancer, gonadotropin releasing hormone (GnRH) I and II may regulate the expression of CXCL3 (29) . CXCL3 has shown to be up-regulated in uterine smooth muscle. Inhibition of CXCL3 and IL6 has been shown in cancer cell lines to reduce Stat3 activation (30) . It is worth noting that the genotyped SNP rs352038 is predicted to act as an eQTL for another inflammatory gene, IL8 (P = 0.007), though this gene is over 300kb distant from rs352038 (31) .
Three other SNPs in or near FABP1 (rs2970294), IL6 (rs2069852), and MSR1 (rs10503574) with significant associations in stage 1 data were also significant in the overall dataset, although they were not replicated in stage 2. The FABP1 gene is a four exon gene on chromosome 2p11.2, which is involved in binding fatty acids and the regulation of lipid transport and metabolism. The FABP1 protein is a target for tamoxifen binding, but its expression is predominantly in the liver, colon, and small intestine (32) . High serum levels of IL6 have been found in endometrial carcinoma, including carcinomas with serous histology (33) . IL6 appears to increase expression of MMP9 protein levels (34, 35) . The MSR1 gene is an 80kb, 11-exon gene on chromosome 8 encoding a macrophage scavenger receptor. Polymorphisms in this gene may play a role in the prostate cancer of Chinese and European-ancestry men (36) (37) (38) . While this association was not replicated in stage 2 data, the signal was more significant in the overall Asian dataset than in stage 1 (OR (95%CI): 0.826 (0.738-
0.925)).
The present study has a number of strengths and weaknesses. The study benefits from its collection of a relatively large number of case and control samples from a number of study sites. The increased sample size and consistent directions of association across a number of study sites strengthens the evidence that these findings-particularly for the CXCL3 and MMP9 SNPs-are much more likely to represent true associations. Limitations include that stage 1 was carried out in an Asian population, and only one SNP per region was selected for the replication study. Some association findings may not extend to non-Asian populations, because of linkage disequilibrium structure differences resulting in false negative results, as may be the case for rs10503574 in MSR1, where linkage disequilibrium blocks as defined by D-prime are quite different between HapMap samples for CEU and CHB+JPT. Minor allele frequencies in European populations were also quite low (Table 3) for three of the five SNPs significant overall, resulting in reduced power to detect associations for CXCL3, IL6, and MSR1. Another limitation is that this analysis was restricted to SNPs in or near (within 20kb) the 64 candidate inflammation genes. Future studies may wish to expand investigations to SNPs known to be eQTLs for inflammatory genes, some of which may be more distant or even in trans to the genes they regulate. Such variations may offer more potent explanations of the expression levels of inflammatory genes. As new resources such as the The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression project (GTEx) are developed, the tools to determine the SNPs controlling the expression of these genes in relevant tissue types will allow more specific tests to be carried out.
In summary, this study found evidence for the involvement of MMP9 and CXCL3 in endometrial carcinogenesis in both Asian-and European-ancestry populations. These findings may warrant additional and functional studies to determine the mechanisms by which these common variants increase disease risk. Future studies may focus on specific eQTL SNPs in the tissues of interest and seek to better explore the link between these inflammatory pathway genes and endometrial carcinogenesis. 
